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Abstract 
 
Purpose - Fatigue is a common and potentially disabling symptom in patients with cancer. It can 
often be effectively reduced by exercise. Yet, effects of exercise interventions might differ across 
subgroups. We conducted a meta-analysis using individual patient data of randomized controlled 
trials (RCTs) to investigate moderators of exercise intervention effects on cancer-related fatigue. 
Methods – We used individual patient data from 31 exercise RCTs worldwide, representing 
4,366 patients, of whom 3,846 had complete fatigue data. We performed a one-step individual 
patient data meta-analysis, using linear mixed-effect models to analyze the effects of exercise 
interventions on fatigue (z-score) and to identify demographic, clinical, intervention- and 
exercise-related moderators. Models were adjusted for baseline fatigue and included a random 
intercept on study level to account for clustering of patients within studies. We identified 
potential moderators by testing their interaction with group allocation, using a likelihood ratio 
test. Results – Exercise interventions had statistically significant beneficial effects on fatigue (β= 
-0.17 [95% confidence interval (CI) -0.22;-0.12]). There was no evidence of moderation by 
demographic or clinical characteristics. Supervised exercise interventions had significantly larger 
effects on fatigue than unsupervised exercise interventions (βdifference= -0.18 [95%CI -0.28;-
0.08]). Supervised interventions with a duration ≤12 weeks showed larger effects on fatigue (β= -
0.29 [95% CI -0.39;-0.20]) than supervised interventions with a longer duration. Conclusions – 
In this individual patient data meta-analysis, we found statistically significant beneficial effects 
of exercise interventions on fatigue, irrespective of demographic and clinical characteristics. 
These findings support a role for exercise, preferably supervised exercise interventions, in 
clinical practice. Reasons for differential effects in duration require further exploration. 
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Registration - PROSPERO, CRD42013003805. 
 
Key words - exercise; fatigue; cancer; individual patient data meta-analysis  
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Introduction 
With an estimated 22.2 million new cancer cases world-wide per year by 2030 (1), attention to 
cancer- and treatment-related symptoms is of great importance. Patients with cancer suffer from 
a variety of symptoms, of which cancer-related fatigue is one of the most frequently reported and 
disabling (2). Fatigue is a potential contributing factor to treatment noncompliance, treatment 
modifications and early discontinuation of treatment, which in turn might have negative impact 
on clinical outcomes (3). Although fatigue levels are typically highest during active treatment, 
elevated levels often persist, even up to 5 years after successful cancer treatment (2, 4). With its 
negative impact on work, daily activities, social activities and mood, fatigue causes significant 
impairment in quality of life among patients with cancer (5, 6).  
 
Since the late 1980s, exercise has been proposed as a potential intervention for the 
prevention and reduction of cancer-related fatigue (7). An increasing number of randomized 
controlled trials (RCTs) in patients with cancer and survivors have evaluated the effects of 
exercise interventions, most of which have included fatigue as one of the main outcomes. Several 
meta-analyses have confirmed the beneficial effects of exercise interventions on fatigue, both 
during and after completion of primary cancer treatment (8-12). A recent meta-analysis, 
comparing effects of pharmaceuticals, exercise, psychological interventions, and combined 
exercise and psychological interventions, showed that the largest improvement in cancer-related 
fatigue was achieved by exercise interventions (weighted effect size: 0.30 [95% confidence 
interval (CI) 0.25; 0.36]) (9).  
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With the availability of an effective intervention for diminishing fatigue, an important 
next step is to investigate: 1) whether or not exercise intervention effects are consistent across 
subgroups of patients with cancer; and 2) intervention characteristics with largest effect. 
Previous meta-analyses evaluated the overall exercise intervention effects on fatigue across a 
wide range of patient groups and interventions (8-12). It is important to determine if there is 
heterogeneity in responses to exercise interventions by investigating the potential moderating 
effects of sociodemographic and clinical characteristics. In addition, identifying characteristics of 
the exercise intervention that maximize the effect of exercise on fatigue will help to target and 
improve exercise programs. However, most RCTs are not adequately powered to identify 
differences in effects between subgroups with the use of interaction tests. Further, conventional 
meta-analyses lack the detailed information on individual patient characteristics that is needed 
for such analyses, resulting in potential ecological bias (i.e. bias that occurs when patient-level 
interactions are influenced by study-level interactions) (13, 14).  
 
Individual patient data meta-analyses offer an opportunity to investigate moderators of 
intervention effects in a more thorough manner. By merging and synchronizing raw individual 
patient data from multiple RCTs, a large amount of detailed information on patient and 
intervention characteristics is available, which facilitates testing interactions at the patient-level 
(13, 14). In the current paper, we report the results of an analysis of individual patient data from 
RCTs in an effort to identify relevant moderators of the effects of exercise interventions on 
fatigue levels in patients with cancer.  
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Methods 
The current study is part of the Predicting OptimaL cAncer RehabIlitation and Supportive care 
(POLARIS) project(15): an international infrastructure and shared database of RCTs 
investigating exercise and psychosocial intervention effects in patients with cancer (registered in 
PROSPERO, CRD42013003805). Effects and potential moderators of the effect of exercise on 
quality of life have been published previously (16). A detailed description of the POLARIS study 
design, including the method of study identification and selection, has been published (15). The 
meta-analysis was conducted in accordance with the PRISMA guidelines. 
 
Briefly, principal investigators of 34 exercise RCTs worldwide have shared individual 
patient data. All principal investigators signed a data sharing agreement, stating that they agreed 
with the POLARIS policy document and were willing to share anonymized data of study 
participants. All individual studies had received approval from their local ethics committees. 
Datasets were imported into the POLARIS database and subsequently harmonized according to 
standardized protocols. Validity checks were performed on improbable or missing values. 
Details on requested variables, and data and project management can be found in the published 
study design (15). All exercise RCTs in POLARIS that reported fatigue outcomes were included 
in the current individual patient data meta-analysis. 
 
Quality assessment 
Methodological quality for each RCT included in the current analysis was assessed using the 
‘risk-of-bias’ tool of the Cochrane Collaboration by two authors independently (MS and LB) 
(17). The following aspects were graded as high, low or unclear quality: random sequence 
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generation (high quality if random component was used; 25 trials), allocation concealment (high 
quality if central, computerized allocation or sequentially numbered sealed envelopes were used; 
24 trials), incomplete outcome (high quality if intention-to-treat analyses were performed and 
missing outcome data were <10% or adequate imputation techniques were used; 25 trials), and 
incomplete reporting (high quality if fatigue was reported such that data could be entered in an 
aggregate data meta-analysis; 24 trials). In addition, we assessed adherence (high quality if 
≥80% of patients attended ≥80% of sessions; 12 trials) and contamination (high quality if no or 
limited exercise was present in the control group; 7 trials). For full quality assessment of the 
included trials, we refer to our previous publication (16).  
 
Outcomes  
The main outcome of our analysis was fatigue after the completion of the exercise intervention, 
measured with Multidimensional Fatigue Inventory (MFI) general fatigue scale(18) (six 
studies(19-26)), Fatigue Assessment Questionnaire (FAQ)(27) (two studies(28, 29)), Schwartz 
Cancer Fatigue Scale (SCFS-6)(30) (three studies(31-33)), revised Piper Fatigue Scale (PFS)(34) 
(two studies(35, 36)), Checklist Individual Strength (CIS)(37) (one study(38)), Functional 
Assessment of Cancer Therapy (FACT)/Functional Assessment of Chronic Illness Therapy 
(FACIT) – Fatigue scale(39) (eight studies(40-47)), the European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Fatigue subscale(48) 
(five studies(49-53)) and Short Form Health Survey (SF-36) Vitality subscale(54) (four 
studies(55-58)). If a study used multiple questionnaires to assess fatigue, we used data from 1) 
the fatigue-specific questionnaire or, 2) the fatigue scale of a cancer-specific quality of life 
questionnaire. 
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Potential moderators 
Potential moderators of the effects of exercise on fatigue were specified based on previous RCTs 
and meta-(regression) analyses(11, 24, 52, 59-61). Potential demographic moderators included 
age, sex, marital status, and education level (Table 1)(16). Potential clinical moderators included 
body mass index (BMI), cancer type, treatment type (surgery, chemotherapy, radiotherapy and 
hormone therapy), and presence of distant metastases.  
 
A selection of intervention characteristics were identified as potential moderators of 
effective exercise programs(16): timing of intervention in relation to primary cancer treatment, 
delivery mode, and intervention duration (Table 1). Potential exercise-related moderators 
included: prescribed exercise frequency, exercise intensity, exercise type, exercise session time 
(i.e. FITT-factors) and exercise volume (i.e. frequency*time) (Table 1). Exercise intensity was 
scored according to the definitions of the American College of Sports Medicine (62). Exercise 
volume was dichotomized into <150 minutes versus ≥ 150 minutes per week, corresponding to 
ACSM’s exercise guidelines for cancer survivors (63). 
 
Statistical analysis 
To allow pooling of the different fatigue questionnaires, we calculated z-scores for each 
individual by subtracting the mean score from the individual score at baseline per fatigue 
questionnaire and dividing the result by the mean standard deviation at baseline per 
questionnaire. Within our analyses, we used a one-step approach, i.e. simultaneously analyzing 
all observations while accounting for clustering of observations within studies (14). We 
conducted all analyses according to the intention-to-treat principle. We used linear mixed effects 
AC
CE
PT
ED
Copyright © 2019 by the American College of Sports Medicine. Unauthorized reproduction of this article is prohibited.
models to analyze the exercise intervention effect on fatigue. The models were adjusted for the 
baseline value of fatigue and included a random intercept on study level to take clustering of 
patients within studies into account. The result, a between-group difference in z-scores, 
corresponds to a Cohen’s d effect size. Absolute effects of 0.2-0.5 were considered small, 0.5-0.8 
as moderate and ≥0.8 as large (64). 
 
To examine whether the effect of exercise interventions on fatigue was moderated by 
patient characteristics, the aforementioned models were extended with interaction terms of the 
group allocation with demographic and clinical characteristics. To prevent ecological bias for 
patient-level interactions, we centered the individual values of potential moderators around their 
mean study values (13). The independent variables in the models were random intercept, group 
allocation (exercise intervention or control), baseline value of fatigue, centered patient 
characteristic, and interaction term (centered patient characteristic*group allocation). The 
potential moderators were examined one-by-one in separate models. We considered a patient-
characteristic to be a moderator if the likelihood ratio test (LRT) indicated a statistically 
significant improvement of the model fit by adding the interaction term.  
 
To identify intervention- and exercise-related moderators, we did not center the 
characteristics, since these generally do not vary within studies. A similar method as described 
above was used, with an interaction term between group allocation and the non-centered 
intervention- or exercise-related characteristic. If this analysis yielded a statistically significant 
interaction, exercise intervention effects were reported per stratum. For studies with multiple 
intervention arms with different characteristics, interaction testing for these specific 
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characteristics was not possible. In those situations, we applied a different approach: the main 
effect models were evaluated using dummy variables for the intervention- or exercise-related 
characteristics. Again, analyses were performed for each characteristic separately. Because of the 
statistically significant moderator effect of delivery mode and the differential exercise 
characteristics between supervised and unsupervised exercise interventions, we investigated 
exercise-related moderators stratified per delivery mode. 
 
Since the majority of patients were women with breast cancer, we also tested overall 
effects on fatigue for patients with breast cancer versus other patients (dichotomized). Because 
no statistically significant interaction was found (p-value LRT 0.7) and effect sizes were similar, 
analyses are presented for all cancer types combined. Statistical significance was set at a 
probability of p<0.05 for all analyses. All statistical analyses were performed using IBM SPSS 
Statistics 21.0 and R version 3.1.1. 
 
Results 
Of the 34 exercise RCTs included in the POLARIS database, 31 evaluated the effect of exercise 
interventions on fatigue, representing 4,366 individual patients. Of these, 2,437 patients were 
randomized to an exercise intervention group and 1,929 to a control group. Baseline 
demographic and clinical characteristics of patients in the exercise intervention group and control 
group are presented separately in Table 2. Patients had a mean age of 54.5 (±11.4) years and a 
mean BMI of 27.2 (±5.2) kg/m
2
. The majority of patients were female (78%) and diagnosed with 
breast cancer (70%). Only a small proportion of patients (2%) had distant metastases at baseline. 
Baseline variables were well balanced over the exercise intervention and control groups. 
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Baseline and end of intervention values were available for analysis of fatigue scores for 3,846 
patients. 
 
Included exercise interventions 
The studies included in the analysis, published between 2003-17, were carried out in the 
Netherlands (19-25, 38, 56), the United States (31-33, 36, 55, 57, 58), Australia (40, 45, 47, 49, 
50, 52), Canada (41-44), Germany (26, 28, 29, 51), United Kingdom (35, 46), and Norway (53). 
Sample sizes ranged from 50 to 330 patients. Of the patients allocated to an exercise intervention 
group, a little over half (50.3%) participated in exercise during primary cancer treatment (Table 3 
and Supplemental Digital Content 1, Appendix, http://links.lww.com/MSS/B757). For the 
majority of patients, the exercise intervention was (partly) supervised (65.3%). Duration of the 
exercise interventions varied between 8 and 52 weeks. Most patients participated in exercise 
interventions that prescribed exercising twice a week (53.6%) at a moderate-vigorous to vigorous 
intensity (48.9%), with session duration of 30-60 minutes (51.7%), and an exercise volume of 
<150 minutes per week (63.2%). A combination of aerobic and resistance exercise was the most 
common exercise type (50.7%). Of the patients allocated to a control group, the majority were 
assigned to a usual care group (63.9%).  
 
Effects on fatigue and moderating effects by patient characteristics 
Exercise interventions had statistically significant beneficial effects on fatigue (β=-0.17 [95% CI 
-0.22; -0.12]) compared to control (Table 4 and Figure 1). Our interaction analyses did not reveal 
statistically significant moderation of demographic or clinical characteristics on the intervention 
effect on fatigue (Table 4).  
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Intervention- and exercise-related moderators 
Timing of the intervention (i.e. during or post primary cancer treatment) was not found to 
influence the effect of exercise on fatigue (Table 5). Supervised exercise interventions had 
statistically significantly larger effects on fatigue than unsupervised exercise interventions 
(difference between subgroups: -0.18 [95% CI: -0.28;-0.08]). Compared to the control group, 
supervised exercise interventions showed statistically significant improvement of fatigue (β=-
0.23 [95% CI: -0.29; -0.17]), while unsupervised exercise interventions did not (β=-0.04 [95%CI 
-0.13; 0.04]) (Table 5 and Figure 1). Within the supervised interventions, duration of the exercise 
intervention was found to moderate the effect of exercise on fatigue. Largest effects on fatigue 
were observed in the supervised exercise interventions with a duration ≤12 weeks (β=-0.29 
[95%CI: -0.39;-0.20]) and smallest effects were observed in supervised exercise interventions 
with duration of >24 weeks (β=-0.11 [95%CI: -0.22; -0.0002]). No other intervention- or 
exercise-related characteristics were identified as moderators of supervised exercise 
interventions. Within the unsupervised interventions, neither duration of the intervention nor 
exercise-related characteristics moderated the effect of exercise interventions on fatigue (Table 
5).  
 
Discussion 
The results of our individual patient data meta-analysis of 31 RCTs indicate that exercise 
interventions have statistically significant beneficial effects on fatigue in patients with cancer. 
For the populations studied, we found no indication that selection of patients based on their 
demographic or clinical characteristics would lead to different effects of exercise interventions 
on fatigue. Instead, beneficial effects on fatigue were observed across all subgroups of patients, 
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supporting a role for exercise in clinical practice for patients with cancer. Strongest effects on 
fatigue were observed in supervised exercise interventions, whereas effects for non-supervised 
interventions were non-significant. 
 
The beneficial effect of exercise interventions on fatigue that we observed in this study is 
in line with previous meta-analyses (8-12).  The overall effect on fatigue in our study was 
statistically significant. Clinical relevance, however, was most pronounced for supervised 
interventions, that showed significant and small effects on fatigue (64). Despite this small 
clinically relevant effect, the clinical relevance is further underlined by the magnitude of the 
problem of fatigue, both  in terms of the number of patients affected and the negative impact on 
patients’ lives, combined with the lack of other, more effective treatment options (9).We recently 
showed that exercise intervention effects on fatigue are larger in patients with worse baseline 
fatigue levels . Exercise intervention effects on fatigue would possibly be larger in trials 
selecting patients based on their baseline fatigue level. Another explanation for the small effect 
may be the joint evaluation of different dimensions of fatigue, resulting in a dilution of the effect 
by the fatigue dimensions that may be less sensitive to exercise (e.g. mental fatigue) (66). 
 
The availability of a large set of individual patient data in our study offered a unique 
opportunity to investigate if the effect of exercise interventions on fatigue differed significantly 
across subgroups of patients with cancer. In previous attempts to identify patient-level 
moderators using meta-regression analyses, chemotherapy and age were found to be statistically 
significant modifiers of the effect of exercise (59, 60). Importantly, in these studies, only 
published aggregate data (i.e., summary statistics, such as mean age) were available. Although 
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meta-regression techniques can be used to explore moderation of exercise effects, they have 
several important disadvantages, including a high risk of bias due to the inability to disentangle 
patient-level heterogeneity from study-level heterogeneity (ecological bias) (13, 67). Therefore, 
the use of individual patient data to investigate the possible influence of patient-level 
characteristics is considered superior (67). In line with a previous single RCT exploring 
moderators of exercise effects on fatigue (19), and our individual patient data meta-analysis of 
moderators of exercise effects on quality of life (16), we did not identify any statistically 
significant demographic or clinical moderators of the effect of exercise on fatigue in patients 
with cancer. Accordingly, our findings support the use of exercise interventions for treatment of 
fatigue across subgroups of patients with cancer. 
 
Of note, the largest group of patients included in the current individual patient data meta-
analysis had breast cancer, followed by prostate cancer and hematological malignancies. 
Although we did not observe a moderating effect of cancer type in our study, the limited number 
of cancer sites included in the RCTs that were part of the present analysis precludes generalizing 
our results to all cancer types. Also, the large majority of patients were treated with curative 
intent. Therefore, the effects of exercise on fatigue in the metastatic setting requires further 
investigation.   
 
We observed that supervised exercise interventions had a larger effect on fatigue than 
unsupervised interventions, which was both statistically significant and clinically relevant. The 
larger effects of supervised exercise interventions may be explained by psychosocial benefits due 
to attention and positive feedback on progress in fitness by the physiotherapist or exercise 
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physiologist delivering the intervention. However, RCTs comparing a supervised exercise 
intervention with a supervised relaxation control group, and thus controlling for attention, also 
showed that effects on fatigue were significantly higher in the exercise group (28, 29). An 
additional feature that may explain the larger effect size of supervised exercise interventions is 
access to proper equipment, permitting appropriate overload, monitoring and feedback, hence 
appropriate intensity. As intensity is often higher in supervised programs (e.g. because of safety 
reasons), teasing out the relative benefit of delivery mode from that of intensity is difficult. In 
addition, the larger effects of supervised exercise interventions may be explained by better 
adherence, greater quality in performance of the exercises, selection of different patients and 
higher fidelity of patient exercise monitoring. Moreover, goals of a supervised exercise program 
may be different from goals of unsupervised exercise interventions (e.g. increasing physical 
fitness versus increasing level of daily physical activity).  
 
Our findings suggest that in the patient groups represented in the included RCTs, 
supervised exercise interventions should be preferred over unsupervised interventions in the 
treatment of fatigue. However, it should be noted that home-based interventions might be 
preferred by some patients, because they are not able or willing to attend supervised 
interventions (68). Moreover, unsupervised interventions have been found to exert positive 
effects on other outcomes, such as physical functioning (16). We recommend that in general, 
patients with cancer should be prescribed a supervised exercise intervention, particularly prior to, 
during and the initial three months following cancer treatment when fatigue effects of treatment 
are greatest. For those who do not have access to a supervised exercise intervention, 
unsupervised exercise interventions could still be useful, and might be augmented with e-Health 
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applications. Further investigation is needed to understand which components are the most 
critical for inclusion in home-based interventions (e.g. including more tailored exercise advice).  
 
Incorporation of supervised exercise into standard care might possibly be more 
demanding in terms of resource allocation and costs. However, a recent trial showed that a 
home-based, low-intensity physical activity program was not likely to be cost-effective for 
fatigue in comparison with usual care, whereas a supervised, moderate-to-high intensity exercise 
program could be considered cost-effective for fatigue depending on the decision-makers’ 
willingness-to-pay (69). Also, our finding that exercise interventions with a duration as short as 
12 weeks already have clinically relevant effects on fatigue, may further support the feasibility of 
incorporating supervised exercise into standard care. 
 
The largest effects of supervised interventions on fatigue were observed in the studies 
with shortest intervention duration. It is possible that adherence to the intervention, and 
consequently the effect of exercise on fatigue, decreases over time (70). At the same time, 
contamination (adoption of exercise by the control group) may increase over time as well (71). In 
addition, there may be a ceiling effect of exercise interventions on fatigue in cancer patients 
whereby 12 weeks or less is sufficient to counteract disease and treatment detriments and further 
duration provides maintenance. Furthermore, we cannot exclude the possibility that this finding 
is partly due to the distribution of other exercise-related characteristics over the duration strata. It 
would be interesting to compare the long-term fatigue outcomes between the interventions with 
different durations, but as only a few studies have examined maintenance of intervention effects 
in the long-term (21, 72-74), this remains to be investigated. In any case, it is an important 
AC
CE
PT
ED
Copyright © 2019 by the American College of Sports Medicine. Unauthorized reproduction of this article is prohibited.
finding that interventions with a duration as short as 12 weeks already have positive and 
clinically relevant effects. 
 
Several methodological limitations of our study should be noted. First, our literature 
search was conducted in 2012 (15), but we also included published study designs in our literature 
search and contacted the principal investigators of these studies. Therefore, we included 13 
studies that were completed after 2012. Although the literature search focused on quality of life 
as primary or secondary outcome, fatigue was assessed in most of the RCTs (31/34) in parallel 
with quality of life. Our main aim was to assess moderators of exercise effects on fatigue using 
individual patient data, and we have no reason to believe that adding more recent studies would 
significantly change our conclusions regarding patient- and disease-related moderators. As 
technology is continuously evolving, intervention characteristics of more recent studies might 
differ from studies conducted in the past. Although technology developments likely take place 
throughout the whole field of exercise interventions, we cannot exclude the possibility that 
adding more recent data could impact some intervention and exercise-related moderators. 
 
Second, despite the inclusion of a large amount of individual patient data, the statistical 
power to detect intervention- and exercise-related moderators was limited because these 
variables are defined at the study-level (14). Especially the identification of significant exercise-
related moderators (FITT-factors), which were stratified by delivery mode, may have been 
compromised by limited power or little variation across studies. Also, we only examined single 
interactions, but there may be more complex multilevel interactions. Furthermore, within meta-
analyses, in general, both patient-level and study-level characteristics can be influenced by 
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(other) study-level characteristics. Centering of patient-level characteristics enabled us to reduce 
the risk of ecological bias by separating patient-level heterogeneity from study-level 
heterogeneity when evaluating demographic and clinical moderators (13). This approach was not 
possible for the analyses on intervention- and exercise-related characteristics, making these 
analyses more prone to influences of other study-level characteristics. Thus, more RCTs that 
include head-to-head comparisons of intervention and exercise-related characteristics are 
warranted to confirm our findings and to better disentangle the effects of different study-level 
determinants, e.g. comparisons between exercise interventions with different exercise types (75, 
76) or post-treatment exercise interventions with different timing in relation to cancer treatment. 
 
Third, adherence to exercise interventions was unknown in the majority of included 
studies and consequently, patients in the exercise groups might have actually been exposed to 
different exercise-related characteristics than assumed. In addition, information on contamination 
was limited, hampering our ability to take the activity level of patients in the control group into 
account. Since adherence and contamination may affect intervention outcomes(41, 77), care 
should be taken to accurately registering both items in order to optimally interpret outcomes of 
exercise interventions. 
 
The present study is the first to collect, synchronize, pool and analyze individual patient 
data on cancer-related fatigue from exercise RCTs worldwide. We applied a careful 
standardization of the outcome data and uniform analytic procedures across all studies. An 
important strength of the study is the availability of a large amount of individual patient data, 
which enabled us to study multiple demographic and clinical patient-level moderators.  
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Conclusions 
In conclusion, we found that exercise has statistically significant beneficial effects on fatigue in 
patients with cancer. These benefits are consistent across subgroups formed on the basis of 
demographic and clinical characteristics. The effect of exercise interventions on fatigue is 
significantly larger when performed under supervision. Differential effects of duration and 
potential roles of adherence and contamination in these findings need further exploration. Our 
results support implementation of exercise, preferably supervised exercise interventions, in 
clinical practice. 
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Figure legends 
 
Figure 1 Forest plot of the effects of exercise interventions on fatigue. 
Exercise effects (between-group differences in z-scores) with 95% confidence intervals are 
presented per intervention, in alphabetical order of first author. Unsupervised interventions 
are presented above the dashed line, and supervised interventions below. Summary estimates 
for unsupervised interventions, supervised intervention and all interventions are provided. 
 
Supplemental Digital Content 1 - Appendix 1:  Descriptives of studies evaluating the effects 
of exercise interventions on fatigue (N=31) 
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Figure 1 
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Table 1 Potential moderators of exercise intervention effects on fatigue 
 
Potential moderator Subcategories 
Demographic moderators  
Age Continuous 
Sex Men 
Women 
Marital status Single 
Married or living with partner 
Education level Low-medium (elementary, primary or secondary school, or lower 
or secondary vocational education) 
High (higher vocational, college or university education) 
Clinical moderators  
Body mass index Continuous 
Cancer type Breast cancer 
Male genitourinary cancer 
Gastrointestinal cancer 
Hematological cancer 
Gynecological cancer 
Other types of cancer 
Surgery Previous or current treatment 
No such treatment 
Chemotherapy Previous or current treatment 
No such treatment 
Radiotherapy Previous or current treatment 
No such treatment 
Hormone therapy Previous or current treatment 
No such treatment 
Presence of distant metastases Yes 
No 
Intervention-related moderators  
Timing of intervention During primary cancer treatment 
Post primary cancer treatment 
Delivery mode Supervised exercise interventions ((part of) exercise sessions 
conducted under supervision) 
Unsupervised exercise interventions (exercise sessions performed 
unsupervised from or at home) 
Intervention duration ≤12 weeks (median 12 weeks, range 3-12) 
>12-24 weeks (median 16 weeks) 
>24 weeks (median 32 weeks, range 26-52) 
Exercise-related moderators  
Exercise frequency Supervised: 
<3 sessions per week 
≥3 sessions per week 
Unsupervised: 
<5 sessions per week 
≥5 sessions per week 
 
Exercise intensity Low-moderate and moderate 
Moderate-vigorous and vigorous 
Exercise type Aerobic exercise (AE) 
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Resistance exercise (RE) 
Combined aerobic and resistance exercise (AE+RE) 
Combined resistance and impact loading exercise (RE+impact) 
Exercise time per session ≤30 minutes 
>30-60 minutes 
>60 minutes 
Exercise volume <150 minutes per week 
≥150 minutes per week 
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Table 2  Demographic and clinical characteristics of individual patients from 31 exercise randomized 
controlled trials included in the meta-analysis 
 Exercise  (n=2437) Control (n=1929) 
Demographic characteristics   
Age, mean (SD) years 54.5 (11.5) 54.5 (11.2) 
Age categories, n (%)    
     < 50 years 831 (34.1) 644 (33.4) 
     50-70 years 1365 (56.0) 1102 (57.1) 
     ≥ 70 years 239 (9.8) 177 (9.2) 
     Unknown 2 (0.1) 6 (0.3) 
Sex, n (%)   
     Men  539 (22.1) 426 (22.1) 
     Women  1898 (77.9) 1503 (77.9) 
Married/living with partner, n (%)    
     Yes  1587 (65.1) 1209 (62.7) 
     No 442 (18.1) 389 (20.2) 
     Unknown 408 (16.7) 331 (17.2) 
Education level, n (%)    
     Low/middle 1149 (47.1) 913 (47.3) 
     High  1033 (42.4) 746 (38.7) 
     Unknown 255 (10.5) 270 (14.0) 
Clinical characteristics   
BMI, mean (SD) kg/m
2
 27.1 (5.1) 27.3 (5.3) 
BMI categories, n (%)   
     Underweight (BMI <18.5 kg/m
2
) 17 (0.7) 22 (1.1) 
     Normal weight (BMI 18.5 to < 25 kg/m
2
) 823 (33.8) 616 (31.9) 
     Overweight (BMI 25 to <30 kg/m
2
) 806 (33.1) 621 (32.2) 
     Obese (BMI ≥ 30 kg/m
2
) 541 (22.2) 436 (22.6) 
     Unknown 250 (10.3) 234 (12.1) 
Cancer Type, n (%)   
     Breast 1706 (70.0) 1355 (70.2) 
     Male genitourinary 326 (13.4) 248 (12.9) 
     Hematological 199 (8.2) 195 (10.1) 
     Gastrointestinal 146 (6.0) 87 (4.5) 
     Gynecological 44 (1.8) 33 (1.7) 
     Other 16 (0.7) 11 (0.6) 
Distant metastasis, n (%)   
     No 2167 (88.9) 1696 (87.9) 
     Yes 47 (1.9) 28 (1.5) 
     N/A (hematological cancer) 199 (8.2) 195 (10.1) 
     Unknown 24 (1.0) 10 (0.5) 
Surgery, n (%)   
     No 299 (12.3) 242 (12.5) 
     Yes 1955 (80.2) 1519 (78.7) 
     N/A (non-solid tumor) 96 (3.9) 97 (5.0) 
     Unknown 87 (3.6) 71 (3.7) 
Chemotherapy, n (%)   
     No 653 (26.8) 526 (27.3) 
     Prior to intervention 954 (39.1) 826 (42.8) 
     During intervention 761 (31.2) 513 (26.6) 
     Unknown 69 (2.8) 64 (3.3) 
Radiotherapy, n (%)   
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     No 990 (40.6) 721 (37.4) 
     Prior to intervention 1004 (41.2) 841 (43.6) 
     During intervention 364 (14.9) 314 (16.3) 
     Unknown 79 (3.2) 53 (2.7) 
Hormone therapy for breast cancer, n (%)   
     No 860 (35.3) 671 (34.8) 
     Yes 631 (25.9) 481 (24.9) 
     N/A (no breast cancer) 731 (30.0) 574 (29.8) 
     Unknown 215 (8.8) 203 (10.5) 
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Table 3  Intervention and exercise-related characteristics of individual patients from 31 
exercise randomized controlled trials included in the meta-analysis 
 All interventions (n=2437) Supervised interventions 
(n=1592) 
Unsupervised interventions 
(n=845) 
 n (%)a n (%)a n (%)a 
Intervention characteristics    
Timing of intervention    
     Pre-during-post cancer treatment 40 (1.6) 40 (2.5) - 
     During cancer treatment 1226 (50.3) 799 (50.2) 427 (50.7) 
     Post cancer treatment 1168 (47.9) 753 (47.3) 415 (49.3) 
Mode of intervention delivery    
     (Partly) Supervised  1592 (65.3) 1592 (100) - 
     Unsupervised 845 (34.7) - 845 (100) 
Duration of intervention    
    ≤ 12 weeks 788 (32.3) 666 (41.8) 122 (14.1) 
    >12 - 24 weeks 751 (30.8) 261 (16.4) 490 (58.0) 
    >24 weeks 698 (28.6) 465 (29.2) 233 (27.6) 
    Unknowne 200 (8.2) 200 (12.6) - 
Type of control groupb    
     Usual care control 1232 (63.9) 836 (59.8) 481 (78.0) 
     Wait list control 392 (20.3) 256 (18.3) 136 (22.0) 
     Attention control 305 (15.8) 305 (21.8) - 
Exercise-related characteristics    
Exercise frequency    
     2 times per week 1306 (53.6) 1237 (77.7) 69 (8.2) 
     3 times per week 315 (12.9) 315 (19.8) - 
     4 times per week 203 (8.3) - 203 (24.0) 
     ≥5 times per week 509 (20.9) 40 (2.5) 469 (55.5) 
     Unknown 104 (4.3) - 104 (12.3) 
Exercise intensity    
     Low-moderate to moderate 1025 (42.1) 425 (26.7) 600 (71.0) 
     Moderate-vigorous to vigorous 1192 (48.9) 1019 (64.0) 173 (20.5) 
     Unknown 220 (9.0) 148 (9.3) 72 (8.5) 
Exercise type    
     AE 686 (28.1) 263 (16.5) 423 (50.1) 
     RE 342 (14.0) 342 (21.5) - 
     AE + RE 1236 (50.7) 814 (51.1) 422 (49.9) 
     RE + Impact training 173 (7.1) 173 (10.9) - 
Exercise session duration    
     ≤ 30 min 928 (38.1) 321 (20.2) 607 (71.8) 
     >30 – 60 min 1260 (51.7) 1022 (64.2) 238 (28.2) 
     >60 min 249 (10.2) 249 (15.6) - 
Exercise volume       
<150 minutes/week 1541 (63.2) 1269 (79.7) 272 (32.2) 
≥150 minutes/week 792 (32.5) 323 (20.3) 469 (55.5) 
Unknown 104 (4.3) - 104 (12.3) 
Abbreviations: AE=aerobic exercise; RE=resistance exercise. 
a
Proportion of patients from exercise groups. 
b
Proportion of patients from control groups (n=1929 for all interventions, n=1397 for supervised interventions, 
n=617 for unsupervised interventions). 
 
 
  
CC
EP
TE
D
Copyright © 2019 by the American College of Sports Medicine. Unauthorized reproduction of this article is prohibited.
Table 4 Effects and patient-level moderators of exercise interventions on fatigue 
 
 Fatigue p-value LRT 
Effect of exercise (95% CI) -0.17 (-0.22;-0.12)*  
   
 Interaction β (95% CI)  
Demographic moderators   
Age  0.00 (-0.01;0.01 0.9 
Sex 0.01 (-0.19;0.21) 0.9 
Marital status  0.06 (-0.07;0.20) 0.3 
Education level 0.03 (-0.09;0.14) 0.6 
 
Clinical moderators 
 
 
 
BMI -0.00 (-0.02;0.01) 0.4 
Cancer type   0.9 
Breast Reference  
Male genitourinary 0.11 (-0.25;0.46)  
Haematological -0.06 (-0.48;0.37)  
Gastrointestinal -0.14 (-0.45;0.17)  
Gynaecological -0.04 (-0.48;0.40)  
Other 0.07 (-0.58;0.72)  
Surgery  -0.05 (-0.32;0.23) 0.7 
Chemotherapy -0.04 (-0.19;0.11) 0.6 
Radiotherapy  0.04 (-0.09;0.16) 0.6 
Hormone therapy for breast cancer 0.03 (-0.13;0.19) 0.7 
Distant metastasis 0.28 (-0.18;0.73) 0.2 
 
*p< 0.05. Betas for patient-level interactions are based on centered values of the potential 
moderators.  
Abbreviations: LRT=likelihood ratio test; CI=confidence interval; BMI=body mass index. 
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Table 5 Effects and intervention- and exercise-related moderators of exercise on fatigue 
 Interaction β  
(95% CI) 
Treatment effect on 
fatigue (95%CI) 
p-value 
LRT 
All exercise interventions  -0.17 (-0.22;-0.12)*  
Intervention characteristics  Stratified analysis  
Timing (post versus during cancer treatment) 0.04 (-0.07;0.14)  0.48 
Delivery mode
$#   0.003 
Unsupervised exercise interventions Reference -0.04 (-0.13; 0.04)  
Supervised exercise interventions -0.18 (-0.28;-0.08)* -0.23 (-0.29; -0.17)*  
    
Supervised exercise interventions  -0.23 (-0.29; -0.17)*  
Intervention characteristics  Stratified analysis  
Duration
# 
  0.048 
≤ 12 weeks
 
Reference -0.29 (-0.39;-0.20)*  
>12-24 weeks 0.04 (-0.13;0.21) -0.25 (-0.41;-0.10)*  
>24 weeks 0.19 (0.04;0.34) -0.11 (-0.22; -0.0002)*  
Exercise-related characteristics    
Frequency -0.03 (-0.17; 0.11)  0.67 
Duration of session   0.87 
<30 minutes Reference   
>30-60 minutes 0.04 (-0.12;0.19)   
>60 minutes 0.01 (-0.20;0.21)   
Exercise volume -0.09 (-0.24;0.05)  0.22 
Intensity
$
   0.93 
Control Reference   
Low-moderate and moderate -0.25 (-0.36;-0.14)*   
Moderate-vigorous and vigorous -0.24 (-0.32;-0.17)*   
Type
$
   0.63 
Control Reference   
AE -0.23 (-0.36;-0.11)*   
AE+RE -0.26 (-0.34 -0.18)*   
RE -0.21 (-0.32;-0.09)*   
RE + impact training -0.14 (-0.32;0.05)   
    
Unsupervised exercise interventions  -0.04 (-0.13; 0.04)  
Intervention characteristics    
Duration   0.23 
≤ 12 weeks
 
Reference   
>12-24 weeks 0.14 (-0.12;0.40)   
>24 weeks -0.03 (-0.32;0.25)   
Exercise-related characteristics    
Frequency -0.20 (-0.42;0.01)  0.06 
Duration of session -0.02 (-0.23;0.19)  0.86 
Exercise volume -0.20 (-0.42;0.01)  0.06 
Intensity
$
   0.15 
Control Reference   
Low-moderate and moderate -0.06 (-0.17;0.06)   
Moderate-vigorous and vigorous 0.11 (-0.09; 0.31)   
Type
$
   0.80 
     Control Reference   
     AE -0.05 (-0.17;0.07)   
     AE+RE -0.02 (-0.17;0.12)   
Abbreviations: CI=confidence interval; LRT=likelihood ratio test; AE=aerobic exercise; RE=resistance exercise. 
*p< 0.05; 
$
Interaction testing is not applicable, therefore differences between subgroups are reported. LRT of the 
model including the intervention or exercise-related characteristic versus the main model is presented. 
#
Stratified 
analysis (significant interaction). 
AC
CE
PT
ED
Copyright © 2019 by the American College of Sports Medicine. Unauthorized reproduction of this article is prohibited.
Appendix 1 Descriptive characteristics of studies evaluating the effects of exercise interventions on fatigue (N=31) 
 
      Intervention Exercise Control  
Author 
(year) 
Acronym 
Country N Age, 
mean 
(SD) 
Sex 
(% female) 
Diagnosis Timing*  Delivery 
mode 
Duration 
(weeks) 
FITT  Fatigue 
questionnaire 
Cadmus, 
(2009)(55)  
IMPACT 
USA 50 54.2 
(9.6) 
100 Breast  During  Unsupervised 6 months F: aim 5x/week 
I: moderate 
T: AE 
T: 30 min 
Usual care SF-36 vitality 
Cormie 
(2015)(40) 
AUS 64 68.4 
(7.1) 
0 Prostate During 
ADT 
Supervised 12 F: 2x/week 
I: moderate-vigorous 
T: RE+AE 
T: 60 min 
Usual care FACT-fatigue 
Courneya 
(2003)(41)  
CANHOPE 
CAN 102 60.2 
(10.8) 
41.2 Colorectal During or 
post 
Unsupervised 16 F: 3-5x/week 
I: moderate  
T: AE 
T: 20-30 min 
Wait-list FACT-fatigue 
Courneya 
(2003)(42) 
REHAB 
CAN 52 58.6 
(5.7) 
100 Breast Post Supervised 15 F: 3x/week 
I: moderate-vigorous 
T: AE 
T: 15-35 min 
Wait-list FACT-fatigue 
Courneya 
(2007)(43) 
START 
CAN 242 49.2 
(9.3) 
100 Breast  During 
CT 
Supervised Median: 
17  
F: 3x/week 
I: moderate-vigorous 
T: AE vs RE 
T: AE: 15-45 min 
Usual care FACT-fatigue 
Courneya 
(2009)(44) 
HELP 
CAN 122 53.2 
(14.8) 
41.0 Hematological During or 
post  
Supervised 12 F: 3x/week 
I: moderate-vigorous 
T: AE 
T: 15-45 min 
Usual care FACT-fatigue 
Daley 
(2007)(35) 
UK 108 51.1 
(8.6) 
100 Breast  Post  Supervised 8  F: 3x/week 
I: moderate-vigorous 
T: AE 
T: 50 min 
Attention 
control vs 
usual care 
PFS 
Duijts NL 207 47.8 100 Breast Post Unsupervised 12 F: 5x per 2 weeks Wait-list SF-36 vitality AC
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      Intervention Exercise Control  
Author 
(year) 
Acronym 
Country N Age, 
mean 
(SD) 
Sex 
(% female) 
Diagnosis Timing*  Delivery 
mode 
Duration 
(weeks) 
FITT  Fatigue 
questionnaire 
(2012)(56) 
EVA 
(5.8) I: vigorous 
T: AE 
T: 45-60 min 
Galvão 
(2010)(50) 
AUS 57 69.8 
(7.3) 
0 Prostate During 
ADT 
Supervised 12 F: 2x/week 
I: moderate 
T: RE+AE 
T: 60 min 
Usual care EORTC QLQ 
C30 fatigue 
Galvão 
(2014)(49) 
RADAR-
exercise 
AUS 100 71.7 
(6.4) 
0 Prostate Post ADT Supervised 6 months F: 2x/week 
I: moderate-vigorous 
T: RE+AE 
T: 60 min 
Usual care 
with PA 
brochure 
EORTC QLQ 
C30 fatigue 
Goedendorp 
(2010)(38) 
NL 144 57.2 
(10.5) 
63.2 Mixed During Unsupervised Mean: 
31.7 
F: towards 5d/week 
I: ? 
T: AE 
T: towards 60 min 
Usual care CIS 
Griffith 
(2009)(36) 
USA 126 60.2 
(10.6) 
38.9 Mixed  During 
CT, RT or 
both 
Unsupervised Mean: 
12.8 
F: 5x/week 
I: low-moderate 
T: AE  
T: 25-35min 
Usual care PFS 
Hayes 
(2013)(45) 
Exercise for 
Health 
AUS 194 52.4 
(8.5) 
100 Breast During  
and/or 
post  
Unsupervised 35 F: aim: ≥ 4x/week 
I: moderate 
T: RE+AE 
T: 20-45 min 
Usual care FACT-fatigue 
Irwin 
(2009)(57) 
YES 
USA 75 55.8 
(8.7) 
100 Breast  
 
 
Post Supervised 6 months F: 3 supervised (+2 
unsupervised) 
I: moderate 
T: AE (walking) 
T: 15-30 min 
Usual care SF-36 vitality 
Kampshoff 
(2015)(19) 
REACT 
NL 277 53.5 
(11.0) 
80.1 Mixed Post  Supervised 12 F: 2x/week 
I: moderate vs vigorous 
T: RE+AE 
T: 60 min 
Wait-list MFI 
Mehnert GER 58 51.9 100 Breast Post  Supervised 10 F: 2x/week Wait-list EORTC QLQ AC
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      Intervention Exercise Control  
Author 
(year) 
Acronym 
Country N Age, 
mean 
(SD) 
Sex 
(% female) 
Diagnosis Timing*  Delivery 
mode 
Duration 
(weeks) 
FITT  Fatigue 
questionnaire 
(2011)(51) (8.5) I: moderate 
T: AE + gymnastics + 
movement games + 
relaxation 
T: 90 min 
C30 fatigue 
Mutrie 
(2007)(46) 
UK 201 51.6 
(9.5) 
100 Breast  During 
CT 
and/or 
RT 
Supervised 12 F: 2 supervised  (+ 1 
unsupervised) 
I: low-moderate 
T: RE+AE 
T: 45 min 
Usual care FACT-fatigue 
Persoon, 
(2017)(20)  
EXIST 
NL 109 52.4 
(11.2) 
36.7 Hematological Post SCT Supervised 18 F: 2x/week 
I: moderate-vigorous 
T: RE+AE 
T: 60 min 
Usual care MFI
#
 
Schmidt 
(2015)(28) 
BEATE 
GER 88 52.5 
(10.0) 
100 Breast During 
CT 
Supervised 12 F: 2x/week 
I: moderate-vigorous 
T: RE 
T: 60 min 
Attention 
control 
FAQ 
Short 
(2015)(47) 
MM4L 
AUS 330 55.9 
(8.3) 
100 Breast Post Unsupervised 16 F: AE: 5x/week; RE: 1-
3x/week 
I: moderate 
T:  RE+AE 
T: AE: 30 min 
Usual care FACIT-fatigue 
Speck 
(2010)(58) 
PAL 
USA 295 56.0 
(8.8) 
100 Breast Post Supervised 52 (13  
super-
vised) 
F: 2x/week 
I: ? 
T: RE 
T: 90 min 
Wait-list SF-36 vitality 
Steindorf 
(2014)(29) 
BEST 
GER 141 56.3 
(8.9) 
100 Breast During 
RT 
Supervised 12 F: 2x/week 
I: moderate-vigorous 
T: RE 
T: 60 min 
Attention 
control 
FAQ 
Taaffe 
(2017)(52)  
AUS 154 69.0 
(9.0) 
0 Prostate During 
ADT 
Supervised 6 months F: 2x/week 
I: moderate-vigorous 
Wait-list EORTC QLQ 
C30 fatigue AC
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      Intervention Exercise Control  
Author 
(year) 
Acronym 
Country N Age, 
mean 
(SD) 
Sex 
(% female) 
Diagnosis Timing*  Delivery 
mode 
Duration 
(weeks) 
FITT  Fatigue 
questionnaire 
T: RE+AE vs RE+impact 
T: 60 min 
Thorsen 
(2005)(53) 
NOR 139 39.4 
(8.3) 
66.9 Mixed Post Unsupervised 14 F: 2x/week or more 
I: moderate-vigorous 
T: RE+AE 
T: aim 30 min 
Usual care EORTC QLQ 
C30 fatigue 
Travier 
(2015)(21); 
van Vulpen 
(2016)(22) 
PACT 
NL 237 50.7 
(8.8) 
91.1 Breast and 
Colon 
During 
CT 
Supervised 18 F: 2x/week 
I: moderate-vigorous 
T: RE+AE 
T: 60 min 
Usual care MFI 
Van Waart 
(2015)(24); 
van Waart 
(2017)(23) 
PACES 
NL 253 51.4 
(9.5) 
95.7 Breast and 
Colon 
During 
CT 
Unsupervised 
vs supervised  
Mean: 
15.9 
F: supervised: 2x/week; 
unsupervised towards 
5x/week 
I: supervised: 
moderate-vigorous 
Unsupervised: 
moderate 
T: supervised: RE+AE; 
unsupervised: AE 
T: supervised: 60min; 
unsupervised: aim 30 
min 
Usual care MFI 
Van Weert 
(2010)(25)  
OncoRev 
NL 133 50.6 
(10.2) 
85.0 Mixed Post Supervised 12 F: 2x/week 
I: AE: moderate-
vigorous, RE: low-
moderate 
T: RE+AE 
T: 120 min 
Wait-list MFI 
Winters-
Stone (2012) 
(31) 
USA 106 62.2 
(6.7) 
100 Breast Post Supervised  52 F: 2x/week supervised 
(+ 1x/week 
unsupervised) 
I: moderate-vigorous 
Attention 
control 
SCFS-6 AC
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      Intervention Exercise Control  
Author 
(year) 
Acronym 
Country N Age, 
mean 
(SD) 
Sex 
(% female) 
Diagnosis Timing*  Delivery 
mode 
Duration 
(weeks) 
FITT  Fatigue 
questionnaire 
T: RE+impact 
T: 60 min 
Winters-
Stone (2013) 
(32) 
USA 71 46.4 
(4.9) 
100 Breast  Post Supervised 52 F: 2x/week supervised + 
1x/week unsupervised 
I: moderate 
T: RE+impact 
T: 60 min 
Attention 
control 
SCFS-6 
Winters-
Stone 
(2015)(33) 
USA 51 70.1 
(8.6) 
0 Prostate During 
ADT 
Supervised 52 F: 2x/wk supervised (+ 
1x/week unsupervised) 
I: moderate 
T: RE+impact 
T: 60 min 
Attention 
control 
SCFS-6 
Wiskemann 
(2011)(26) 
GER 80 48.4 
(14.4) 
31.3 Hematological Pre-
during-
post  
Supervised Median 
exercise: 
16.4 
Control: 
15.7 
F: 5x/week 
I: moderate-vigorous 
T: RE+AE 
T: AE: 20-40 min 
Attention 
control 
MFI 
 
Descriptive characteristics are based on the data in the POLARIS database. Abbreviations: SD=standard deviation; ADT= androgen deprivation 
therapy; CT=chemotherapy; RT=radiotherapy; SCT=stem cell transplantation; AE=aerobic exercise; RE=resistance exercise; SF-36 vitality= 
Short Form-36 Item Health Survey vitality subscale; FACT-fatigue=Functional assessment of cancer treatment fatigue scale; PFS=revised Piper 
fatigue scale; EORTC QLQ C30 fatigue= European Organization for Research and Treatment of Cancer Quality of Life Questionnaire – Core 30 
fatigue subscale; CIS=Checklist individual strength; MFI=Multidimensional fatigue inventory; FAQ=Fatigue Assessment Questionnaire; SCFS-
6=Schwartz Cancer Fatigue Scale. *Timing of the exercise intervention in relation to treatment. AC
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